A SURVEY OF RHEUMATOLOGY PATIENTS' SATISFACTION TO SWITCHING FROM ORIGINATOR TO BIOSIMILAR AGENTS

被引：0
|
作者：
Ng, C. R. [1 ]
Samec, S. [1 ]
Kavanagh, P. [1 ]
Mccarthy, G. [1 ]
Donnelly, S. [1 ]
Wilson, A. G. [1 ]
机构：
[1] Mater Misericordiae Univ Hosp, Dept Rheumatol, Dublin, Ireland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.2981
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0805
引用
收藏
页码：1427 / 1427
页数：1
相关论文
共 50 条
  • [41] Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study
    Hellstrom, Per M.
    Gemmen, Eric
    Ward, Heather A.
    Koo, Hyewon
    Faccin, Freddy
    Xue, Zhenyi
    Malmborg, Petter
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (12) : 1435 - 1442
  • [42] A Survey Among IBD Patients Following Switching From Originator Infliximab to Its Biosimilars
    Doan, Anh Trinh
    Johnson, Christopher
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S867 - S867
  • [43] Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab
    Bettey, M.
    Downey, L.
    Underhill, C.
    Callaghan, J.
    Rush, M.
    Ahmed, I.
    Cummings, F.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S43 - S44
  • [44] Evaluation of the nocebo effect after switching from etanercept or adalimumab originator to a biosimilar: a retrospective study of patients with inflammatory rheumatism
    Hagege, O.
    Brevet, P.
    Gerard, B.
    Duhamel, E.
    Mihailescu, S. -d.
    Alcaix, D.
    Weber, A. -J
    Marcelli, C.
    Grosjean, J.
    Varin, R.
    Lequerre, T.
    Vittecoq, O.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2025, 43 (01) : 87 - 95
  • [45] Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease
    van Hoeve, K.
    Dreesen, E.
    Hoffman, I.
    Ferrante, M.
    Gils, A.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S313 - S314
  • [46] IN PATIENTS WITH IBD SWITCHING FROM ORIGINATOR INFLIXIMAB (REMICADE) TO BIOSIMILAR INFLIXIMAB (CT-P13) IS SAFE AND EFFECTIVE
    Rahmany, S.
    Cotton, S.
    Garnish, S.
    Brown, M.
    Saich, R.
    Lloyd, D.
    Gordon, J. N.
    GUT, 2016, 65 : A89 - A89
  • [47] Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet’s disease
    Giuseppe Lopalco
    Vincenzo Venerito
    Luca Cantarini
    Giacomo Emmi
    Domenico Prisco
    Florenzo Iannone
    Internal and Emergency Medicine, 2019, 14 : 719 - 722
  • [48] SWITCHING FROM INFLIXIMAB ORIGINATOR TO A BIOSIMILAR DOES NOT AFFECT PHARMACOKINETICS, IMMUNOGENICITY AND EFFICACY IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    van Hoeve, Karen
    Dreesen, Erwin
    Hoffman, Ilse
    Ferrante, Marc
    Ann, Gils
    Vermeire, Severine
    GASTROENTEROLOGY, 2019, 156 (06) : S199 - S199
  • [49] Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review
    Gisbert, Javier P.
    Chaparro, Maria
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2018, 41 (06): : 389 - 405
  • [50] Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy
    Convertino, Irma
    Tuccori, Marco
    Lucenteforte, Ersilia
    Mosca, Marta
    Turchetti, Giuseppe
    Lorenzoni, Valentina
    Trieste, Leopoldo
    Ferraro, Sara
    Leonardi, Luca
    Roberto, Giuseppe
    Luciano, Nicoletta
    Blandizzi, Corrado
    Gini, Rosa
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 477 - 478
12345